-
Something wrong with this record ?
Flubendazole exhibits anti-glioblastoma effect by inhibiting STAT3 and promoting cell cycle arrest
B. Vítovcová, V. Skarková, R. Havelek, J. Soukup, A. Pande, K. Caltová, E. Rudolf
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't
NLK
Directory of Open Access Journals
from 2011
Free Medical Journals
from 2011
Nature Open Access
from 2011-12-01
PubMed Central
from 2011
Europe PubMed Central
from 2011
ProQuest Central
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Open Access Digital Library
from 2011-01-01
Health & Medicine (ProQuest)
from 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
from 2011
Springer Nature OA/Free Journals
from 2011-12-01
- MeSH
- Apoptosis MeSH
- Cell Cycle MeSH
- Adult MeSH
- Glioblastoma * pathology MeSH
- Cell Cycle Checkpoints MeSH
- Humans MeSH
- Mebendazole pharmacology therapeutic use MeSH
- Cell Line, Tumor MeSH
- Brain Neoplasms * pathology MeSH
- Cell Proliferation MeSH
- STAT3 Transcription Factor metabolism MeSH
- Check Tag
- Adult MeSH
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
Glioblastoma multiforme (GBM) belongs to most aggressive and invasive primary brain tumor in adults whose prognosis and survival remains poor. Potential new treatment modalities include targeting the cytoskeleton. In our study, we demonstrated that repurposed drug flubendazole (FLU) significantly inhibits proliferation and survival of GBM cells. FLU exerted its effect by affecting microtubule structure and our results also suggest that FLU influences tubulins expression to a certain degree. Moreover, FLU effects decreased activation of STAT3 and also partially inhibited its expression, leading to upregulation of p53 signaling pathway and subsequent cell cycle arrest at G2/M phase as well as caspase-dependent cell death in GBM cells. These results suggest FLU as a promising agent to be used in GBM treatment and prompting further testing of its effects on GBM.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc23010450
- 003
- CZ-PrNML
- 005
- 20230801132432.0
- 007
- ta
- 008
- 230718s2023 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41598-023-33047-9 $2 doi
- 035 __
- $a (PubMed)37045903
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Vítovcová, Barbora $u Department of Medical Biology and Genetics, Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, 500 03, Hradec Králové, Czech Republic. vitovcob@lfhk.cuni.cz
- 245 10
- $a Flubendazole exhibits anti-glioblastoma effect by inhibiting STAT3 and promoting cell cycle arrest / $c B. Vítovcová, V. Skarková, R. Havelek, J. Soukup, A. Pande, K. Caltová, E. Rudolf
- 520 9_
- $a Glioblastoma multiforme (GBM) belongs to most aggressive and invasive primary brain tumor in adults whose prognosis and survival remains poor. Potential new treatment modalities include targeting the cytoskeleton. In our study, we demonstrated that repurposed drug flubendazole (FLU) significantly inhibits proliferation and survival of GBM cells. FLU exerted its effect by affecting microtubule structure and our results also suggest that FLU influences tubulins expression to a certain degree. Moreover, FLU effects decreased activation of STAT3 and also partially inhibited its expression, leading to upregulation of p53 signaling pathway and subsequent cell cycle arrest at G2/M phase as well as caspase-dependent cell death in GBM cells. These results suggest FLU as a promising agent to be used in GBM treatment and prompting further testing of its effects on GBM.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a lidé $7 D006801
- 650 12
- $a glioblastom $x patologie $7 D005909
- 650 _2
- $a nádorové buněčné linie $7 D045744
- 650 _2
- $a kontrolní body buněčného cyklu $7 D059447
- 650 _2
- $a mebendazol $x farmakologie $x terapeutické užití $7 D008463
- 650 _2
- $a proliferace buněk $7 D049109
- 650 12
- $a nádory mozku $x patologie $7 D001932
- 650 _2
- $a apoptóza $7 D017209
- 650 _2
- $a buněčný cyklus $7 D002453
- 650 _2
- $a transkripční faktor STAT3 $x metabolismus $7 D050796
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Skarková, Veronika $u Department of Medical Biology and Genetics, Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, 500 03, Hradec Králové, Czech Republic
- 700 1_
- $a Havelek, Radim $u Department of Medical Biochemistry, Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, 500 03, Hradec Králové, Czech Republic
- 700 1_
- $a Soukup, Jiří $u The Fingerland Department of Pathology, Faculty of Medicine and University Hospital in Hradec Králové, Charles University, Sokolská 581, 500 05, Hradec Králové, Czech Republic
- 700 1_
- $a Pande, Ananya $u Department of Medical Biology and Genetics, Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, 500 03, Hradec Králové, Czech Republic
- 700 1_
- $a Caltová, Kateřina $u Department of Medical Biology and Genetics, Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, 500 03, Hradec Králové, Czech Republic
- 700 1_
- $a Rudolf, Emil $u Department of Medical Biology and Genetics, Faculty of Medicine in Hradec Králové, Charles University, Šimkova 870, 500 03, Hradec Králové, Czech Republic
- 773 0_
- $w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 13, č. 1 (2023), s. 5993
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/37045903 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20230718 $b ABA008
- 991 __
- $a 20230801132429 $b ABA008
- 999 __
- $a ok $b bmc $g 1963084 $s 1196715
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2023 $b 13 $c 1 $d 5993 $e 20230412 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
- LZP __
- $a Pubmed-20230718
